|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We focused on signaling by chemokine CXCL12, a hallmark molecule secreted by CAFs, and receptor CXCR4, a driver of tumor progression and metastasis in TNBC.
|
29416611 |
2018 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We also demonstrated that restored expression of CXCL12 dampened miR-448-mediated suppression of tumor progression, which suggests the important role of miR-448 in tumor progression.
|
26103953 |
2015 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To investigate CXCL12-CXCR4 signaling in ovarian cancer and establish effects of inhibiting this pathway on tumor progression and survival, we designed a Gaussia luciferase complementation imaging reporter system to detect CXCL12 binding to CXCR4 in ovarian cancer cells.
|
22241961 |
2011 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This review focuses on the state-of-the-art of CXCL12/CXCR4 signaling axis in pancreatic cancer and its role in tumor progression.
|
24033967 |
2013 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
These results underscore the importance of retaining CXCL12 expression to sensitize colorectal carcinomas to anoikis and minimize tumor progression.
|
20877573 |
2010 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These findings demonstrate the first evidence for epigenetic regulation of CXCR4 in human cancers, providing new insights into the role of CXCR4/CXCL12 interactions in tumor progression.
|
15662133 |
2005 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Therefore, High expression of C-X-C chemokine receptor type 4/stromal cell-derived factor-1 which is essential in tumor progression can predict poor survival that may provide more advance prognostic clues to colorectal cancer patients.
|
28621237 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
There has evidence showing that C-X-C chemokine receptor type 4 (CXCR-4) and its ligand, stromal cell-derived factor-1 (SDF-1), plays an important role in cancer progression and metastasis.
|
28739729 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The SDF-1α chemokine (CXCL12) is a potent bioactive chemoattractant known to be involved in hematopoietic stem cell homing and cancer progression.
|
28279922 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The CXCR4-CXCL12 interaction in cancer elicits biological activities that result in tumor progression and has accordingly been the subject of significant investigation for detection and treatment of the disease.
|
30883140 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The CXCR4 receptor antagonist plerixafor (AMD3100) is raising interest as an anti-cancer agent that disrupts the CXCL12-CXCR4 chemokine - receptor interaction between neoplastic cells and their microenvironment in tumor progression and metastasis.
|
29776413 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 (SDF-1) plays an important role in tumor progression and are associated with angiogenesis.
|
25367885 |
2015 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The chemokine CXCL12 (also termed SDF-1, stromal cell-derived factor-1) and its receptors CXCR4 and CXCR7 are known to play a pivotal role in tumor progression including glioblastomas (GBM).
|
26821357 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The chemokine CXCL12 and its receptor CXCR4 have been found to be important in tumor progression.
|
21298365 |
2012 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The CXCL12-CXCR4 signaling axis plays an important role in tumor progression and metastasis, but also in treatment-induced recruitment of CXCR4-expressing cytotoxic immune cells.
|
31802362 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The CXCL12-CXCR4 chemokine axis plays an important role in cell trafficking as well as in tumor progression.
|
28936810 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The stromal cell-derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4) axis and Wingless and INT-1 (Wnt)/β-catenin pathway has been related to cancer progression.
|
24023356 |
2013 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The CXCL12/CXCR4 axis is involved in tumor progression, angiogenesis, metastasis, and survival.
|
20484021 |
2010 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The CXCL12/CXCR4 pathway, which is involved in biological phenomena such as inflammation, lymphoid homing and regeneration, may play an important role in tumor progression and distant metastasis, especially in organ-selective metastasis.
|
19360294 |
2009 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Signals mediated by CXCL12 (SDF1) and its receptor CXCR4 are centrally involved in cancer progression, both directly by activating cancer cells and indirectly by inducing angiogenesis plus recruiting T regulatory and plasmacytoid dendritic immune cells.
|
22025564 |
2011 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Recent studies suggest that SDF-1 and CXCR4 are expressed in certain cancer cells, and malignant cells use this chemokine/receptor system to promote tumor progression and metastasis.
|
26406413 |
2015 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Moreover, CXCR4, with its ligand CXCL12, played a critical role in tumor progression induced by TCF12 via activation of the MAPK/ERK and PI3K/AKT signaling pathways.
|
31534521 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Moreover, CnP strongly decreased the various cytokines involved in cancer progression, such as interleukin (IL)-6, IL-8, C-C motif chemokine ligand 2 (CCL2), and C-X-C motif chemokine ligand 12 (CXCL12), secreted by CAF.
|
30353606 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Mechanisms that regulate availability of CXCL12 in tumor microenvironments will substantially impact cancer progression and ongoing efforts to target the CXCL12-CXCR4 pathway for cancer chemotherapy.
|
22266857 |
2012 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Interactions between CXCR4 and its ligand CXCL12 have been shown to be involved in cancer progression in colorectal cancer (CRC).
|
21349176 |
2011 |